Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function

TriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive Officer

Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease

Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.